Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to 0.54%.

  • Allogene Therapeutics' Return on Capital Employed fell 300.0% to 0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.49% for FY2024, which is 200.0% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Return on Capital Employed is 0.54%, which was down 300.0% from 0.56% recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Return on Capital Employed high stood at 0.18% for Q4 2021, and its period low was 0.56% during Q2 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.49% (2023), whereas its average is 0.4%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 1300bps in 2021, then crashed by -2600bps in 2023.
  • Allogene Therapeutics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then tumbled by -135bps to 0.42% in 2022, then fell by -23bps to 0.51% in 2023, then decreased by 0bps to 0.51% in 2024, then decreased by -5bps to 0.54% in 2025.
  • Its Return on Capital Employed stands at 0.54% for Q3 2025, versus 0.56% for Q2 2025 and 0.54% for Q1 2025.